Search research articles
Contact Us
Filters
Showing results (81-90 of 114) with videos related to
Page
of 12
Sort By:
Gastroenterologie Clinique Et Biologique
|
April 25, 2006
Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial
Emmanuel Mitry, Michel Ducreux, Mahmoud Ould-Kaci, et al.
Annales D'Endocrinologie
|
September 3, 2013
Malignant insulinoma: recommendations for characterisation and treatment
Eric Baudin, Philippe Caron, Catherine Lombard-Bohas, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
June 7, 2013
Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort
Simon Pernot, Emmanuel Mitry, Emmanuelle Samalin, et al.
Presse Medicale (Paris, France : 1983)
|
May 27, 2014
[Malignant insulinoma: recommendations for workup and treatment]
Eric Baudin, Philippe Caron, Catherine Lombard-Bohas, et al.
The International Journal of Biological Markers
|
May 17, 2011
Chromogranin A measurement in metastatic well-differentiated gastroenteropancreatic neuroendocrine carcinoma: screening for false positives and a prospective follow-up study
Delphine Vezzosi, Thomas Walter, Agnès Laplanche, et al.
Gut
|
October 16, 2010
Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301)
Laetitia Dahan, Frank Bonnetain, Marc Ychou, et al.
BMC Cancer
|
January 7, 2022
OncoSNIPE® Study Protocol, a study of molecular profiles associated with development of resistance in solid cancer patients
Sébastien Vachenc, Jessica Gobbo, Sarah El Moujarrebe, et al.
International Journal of Cancer
|
April 27, 2011
Evaluation of predictive models in daily practice for the identification of patients with Lynch syndrome
Christophe Tresallet, Antoine Brouquet, Catherine Julié, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 30, 2004
Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803
Olivier Bouché, Jean Luc Raoul, Franck Bonnetain, et al.
British Journal of Cancer
|
November 8, 2013
Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study
T Aparicio, M Svrcek, A Zaanan, et al.
Page
of 12
Search research articles
Search
Showing results (81-90 of 114) with videos related to
Sort By:
Page
of 12
Gastroenterologie Clinique Et Biologique
|
April 25, 2006
Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial
Emmanuel Mitry, Michel Ducreux, Mahmoud Ould-Kaci, et al.
Annales D'Endocrinologie
|
September 3, 2013
Malignant insulinoma: recommendations for characterisation and treatment
Eric Baudin, Philippe Caron, Catherine Lombard-Bohas, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
June 7, 2013
Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort
Simon Pernot, Emmanuel Mitry, Emmanuelle Samalin, et al.
Presse Medicale (Paris, France : 1983)
|
May 27, 2014
[Malignant insulinoma: recommendations for workup and treatment]
Eric Baudin, Philippe Caron, Catherine Lombard-Bohas, et al.
The International Journal of Biological Markers
|
May 17, 2011
Chromogranin A measurement in metastatic well-differentiated gastroenteropancreatic neuroendocrine carcinoma: screening for false positives and a prospective follow-up study
Delphine Vezzosi, Thomas Walter, Agnès Laplanche, et al.
Gut
|
October 16, 2010
Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301)
Laetitia Dahan, Frank Bonnetain, Marc Ychou, et al.
BMC Cancer
|
January 7, 2022
OncoSNIPE® Study Protocol, a study of molecular profiles associated with development of resistance in solid cancer patients
Sébastien Vachenc, Jessica Gobbo, Sarah El Moujarrebe, et al.
International Journal of Cancer
|
April 27, 2011
Evaluation of predictive models in daily practice for the identification of patients with Lynch syndrome
Christophe Tresallet, Antoine Brouquet, Catherine Julié, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 30, 2004
Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803
Olivier Bouché, Jean Luc Raoul, Franck Bonnetain, et al.
British Journal of Cancer
|
November 8, 2013
Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study
T Aparicio, M Svrcek, A Zaanan, et al.
Page
of 12